Latest Market Expansion News

Cettire Limited reports a slight 1.7% increase in sales revenue for the year-to-date FY25 amid ongoing global luxury market challenges, including US tariff impacts and volatile demand. The company focuses on emerging markets expansion and improving profitability despite margin pressures.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

FOS Capital has secured $3.7 million through a placement to fund its acquisition of Aldridge Traffic Systems, aiming to expand its footprint in the Australian lighting market. The deal includes key assets and intellectual property, positioning FOS for accelerated growth.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.

Imricor Medical Systems has secured CE Mark approval for its NorthStar Mapping System ahead of schedule, marking a pivotal shift to software-centric MRI-guided cardiac interventions across Europe and the Middle East.

Advance ZincTek Limited signals a strong financial turnaround for FY25, expecting a $1.75 million profit before tax driven by increased US sales and strategic operational shifts.

icetana AI has forged a multi-year strategic partnership with SoftBank Robotics Group, including a A$1.87 million equity investment and exclusive distribution rights in Japan, setting the stage for accelerated growth and innovation in the Asia-Pacific region.

Proteomics International has completed a $12 million capital raise, including a heavily oversubscribed Share Purchase Plan, to fast-track the rollout of its innovative diagnostic tests in Australia and the USA.

Cardiex Limited has successfully raised $2.4 million through an institutional placement to boost manufacturing and commercial activities for its CONNEQT Pulse device.

OncoSil Medical has launched a Security Purchase Plan offering discounted shares and free options to eligible shareholders, aiming to accelerate commercialization of its pancreatic cancer treatment device.

Cann Group Limited has resolved its legal dispute with Rua Biosciences, paving the way for new commercial agreements to supply medicinal cannabis products across Australia and New Zealand.